ACRS

Nov 05, 10:17 AMAclaris Therapeutics reports Q3 2026 results with non-GAAP EPS -$0.12 and revenue $1.5M, beating EPS and revenue estimates

Peers: UPB GENB ALMS ATTO ANAB ZURA AVTX EVMN TRAX CNTB

| Held by: VTI IWM VXF XPH VTWO IWO FESM IBB SCHA DWAS

Scroll to Statements

Index	RUT
Market Cap	602.11M
Enterprise Value	399.35M
Income	-79.63M
Sales	6.40M
Book/sh	1.11
Cash/sh	1.32
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	73
IPO	Oct 07, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	94.08
P/B	3.51
P/C	2.94
P/FCF	-
EV/EBITDA	-
EV/Sales	62.40
Quick Ratio	3.46
Current Ratio	3.46
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-0.59
EPS next Y	-0.69
EPS next Q	-0.17
EPS this Y	-15.26%
EPS next Y	-13.38%
EPS next 5Y	-12.29%
EPS past 3/5Y	26.48% 15.08%
Sales past 3/5Y	-35.93% 3.84%
EPS Y/Y TTM	57.25%
Sales Y/Y TTM	-59.34%
EPS Q/Q	-3.86%
Sales Q/Q	-55.11%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	25.79% 16.54%

Insider Own	24.55%
Insider Trans	0.00%
Inst Own	68.49%
Inst Trans	4.81%
ROA	-40.66%
ROE	-55.51%
ROIC	-63.28%
Gross Margin	10.64%
Oper. Margin	-1412.40%
Profit Margin	-1244.09%
SMA20	4.89%
SMA50	-15.95%
SMA200	-14.29%
Trades

Shs Outstand	150.83M
Shs Float	111.06M
Short Float	13.53%
Short Ratio	5.31
Short Interest	15.03M
52W High	6.60 -41.14%
52W Low	2.10 85.00%
Volatility	7.18% 7.92%
ATR (14)	0.30
RSI (14)	46.42
Beta	0.96
Rel Volume	1.09
Avg Volume	2.83M
Volume	2,382,560

Perf Week	-2.14%
Perf Month	2.51%
Perf Quarter	-34.15%
Perf Half Y	-21.20%
Perf YTD	29.07%
Perf Year	71.15%
Perf 3Y	-29.11%
Perf 5Y	-76.40%
Perf 10Y	-81.39%
Recom	1.15
Target Price	10.75
Prev Close	3.61
Price	3.88
Change %	7.62%

Consensus

Strong Buy

Avg. Price Target

$10.75

Implied Upside

+176.7%

Analysts14incl. previous ratings

Rating Distribution13 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 01, 2026	Initiated	CCanaccord Genuity	Buy	$10	+157.4%
May 05, 2026	Initiated	GGuggenheim	Buy	$12	+208.9%
Apr 16, 2026	Initiated	OOppenheimer	Outperform	$10	+157.4%
Jul 10, 2025	Resumed	PPiper Sandler	Overweight	$6	+54.4%
May 28, 2025	Initiated	WWedbush	Outperform	$8	+105.9%
Mar 18, 2025	Resumed	CCantor Fitzgerald	Overweight
Dec 23, 2024	Upgrade	HH.C. Wainwright	Neutral → Buy	$20	+414.8%
Nov 20, 2024	Upgrade	CCantor Fitzgerald	Neutral → Overweight
Nov 19, 2024	Upgrade	LLeerink Partners	Market Perform → Outperform	$2 → $7	+80.2%
Nov 19, 2024	Upgrade	JJefferies	Hold → Buy	$2 → $7	+80.2%
Nov 19, 2024	Upgrade	BBTIG Research	Neutral → Buy	$8	+105.9%
Nov 18, 2024	Upgrade	PPiper Sandler	Neutral → Overweight	$3 → $13	+234.6%
Jan 22, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral
Nov 13, 2023	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Oct 03, 2023	Initiated	EEvercore ISI	Outperform	$22	+466.3%
Dec 14, 2022	Initiated	SStifel	Buy	$29	+646.5%
Dec 01, 2022	Initiated	GGoldman	Buy	$25	+543.5%
Oct 06, 2022	Initiated	BBTIG Research	Buy	$32	+723.7%
Jul 23, 2021	Resumed	JJefferies	Buy	$27 → $32	+723.7%
Jun 15, 2021	Initiated	PPiper Sandler	Overweight	$30	+672.2%

Nov-05-26 07:15AM	Aclaris: Q3 Earnings Snapshot (Associated Press)
06:59AM	Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update (GlobeNewswire)
Oct-27-26 08:40AM	Aclaris Reports Positive Asthma, Eczema Drug Trial Results So, Why Is ACRS Stock Down Nearly 8%? (Stocktwits)
06:43AM	Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
06:00AM	Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Ra Bispecific ATI-052 in Atopic Dermatitis (AD) and Asthma (GlobeNewswire)
08:00AM	Loading…
Sep-03-26 08:00AM	Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-06-26 04:35PM	Aclaris Therapeutics Receives Fast Track Designation for Modzatinib (ATI-2138) for Moderate to Severe Lichen Planus (LP) (GlobeNewswire)
07:18AM	Aclaris: Q2 Earnings Snapshot (Associated Press)
06:59AM	Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update (GlobeNewswire)
May-28-26 08:30AM	Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference (GlobeNewswire)
May-08-26 08:30AM	Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference (GlobeNewswire)
May-07-26 07:07AM	Aclaris: Q1 Earnings Snapshot (Associated Press)
06:59AM	Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update (GlobeNewswire)
Apr-28-26 06:30AM	Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Ra Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor (GlobeNewswire)
Apr-27-26 04:45PM	Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 (GlobeNewswire)
08:30AM	Loading…
Apr-08-26 08:30AM	Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference (GlobeNewswire) +5.33%
Mar-27-26 10:10AM	Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138 (GlobeNewswire)
Mar-20-26 11:00AM	Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-18-26 06:55AM	Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis (GlobeNewswire) -5.67%
Mar-03-26 07:00AM	Aclaris Therapeutics to Participate in the Leerink Partners 2026 Global Healthcare Conference (GlobeNewswire)
Feb-26-26 10:59AM	Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference (MarketBeat) -5.44%
09:45AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Aclaris: Q4 Earnings Snapshot (Associated Press Finance)
06:58AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-25-26 12:15PM	Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-24-26 09:55PM	Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates (Zacks)
07:00AM	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Ra Antibody ATI-052 (GlobeNewswire)
Feb-12-26 07:27PM	Aclaris Therapeutics Touts TSLP and ITK Pipeline, Sets Up Multiple Clinical Readouts for 2026 (MarketBeat) -5.06%
Feb-04-26 07:00AM	Aclaris Therapeutics to Participate in Two February Healthcare Conferences (GlobeNewswire)
Jan-27-26 01:12PM	Aclaris Hair Loss Drug Shows Faster Results Than Pfizer's Drug (Benzinga)
06:55AM	Loading…
06:55AM	Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA) (GlobeNewswire)
Jan-13-26 07:44AM	Aclaris Therapeutics initiates Phase 1b proof-of-concept trial of ATI-052 (TipRanks)
Jan-12-26 06:55AM	Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052 (GlobeNewswire)
Jan-06-26 06:59AM	Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Ra Bispecific Antibody ATI-052 Supporting Expedited Clinical Development (GlobeNewswire)
Dec-19-25 04:01PM	Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI) (GlobeNewswire)
Nov-25-25 08:00AM	Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-06-25 08:05AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:08AM	Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
06:59AM	Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-04-25 06:25PM	Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates (Zacks) -7.81%
Oct-29-25 07:30AM	Aclaris Therapeutics to Participate in Three November Healthcare Conferences (GlobeNewswire)
Oct-21-25 12:00PM	What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now? (Zacks) +18.41%
Sep-30-25 07:00AM	Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 (GlobeNewswire)
Sep-21-25 09:13AM	Acadian Increases Stake in Aclaris Therapeutics, Inc. (ACRS) as Phase 2a Data Gains Spotlight (Insider Monkey)
Sep-18-25 10:05AM	Strength Seen in Xencor (XNCR): Can Its 7.3% Jump Turn into More Strength? (Zacks) +7.73%
Sep-09-25 07:00AM	Aclaris Therapeutics Announces Late-Breaking Abstract and Oral Presentation On ATI-2138 Phase 2a Results at the 2025 European Academy of Dermatology and Venereology (EADV) Congress (GlobeNewswire)
Aug-27-25 08:00AM	Aclaris Therapeutics to Participate in Two September Healthcare Conferences (GlobeNewswire)
Aug-17-25 11:41PM	Aclaris Therapeutics Reports Positive Phase 2a Clinical Trial Results for ATI-2138 (Insider Monkey)
Aug-07-25 08:05AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:07AM	Aclaris: Q2 Earnings Snapshot (Associated Press Finance)
06:59AM	Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-04-25 10:00AM	Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Jul-30-25 10:00AM	Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-29-25 04:01PM	Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints (GlobeNewswire) -7.74%
Jul-28-25 08:45AM	Aclaris Therapeutics Announces Leadership Transition (GlobeNewswire)
Jul-15-25 08:59AM	Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases (Insider Monkey)
Jun-30-25 09:31AM	Aclaris Therapeutics Added to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire)
Jun-26-25 04:01PM	Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference (GlobeNewswire) -5.77%
Jun-23-25 06:59AM	Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 (GlobeNewswire)
Jun-02-25 06:59AM	Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis (GlobeNewswire)
May-28-25 09:20AM	Aclaris Therapeutics to Participate in Two June Healthcare Conferences (GlobeNewswire) +11.02%
May-09-25 07:00AM	Aclaris Therapeutics to Participate in the HC Wainwright "HCW@Home" Series (GlobeNewswire)
May-08-25 08:00AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:57AM	Aclaris: Q1 Earnings Snapshot (Associated Press Finance)
06:50AM	Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-25 07:00AM	Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-23-25 06:44AM	Aclaris Therapeutics receives FDA approval for Phase Ia/Ib trial of ATI-052 (Clinical Trials Arena) +8.18%
Apr-22-25 06:59AM	Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody (GlobeNewswire)
Mar-19-25 08:21AM	Aclaris Therapeutics assumed with an Overweight at Cantor Fitzgerald (TipRanks)
Mar-04-25 07:00AM	Aclaris Therapeutics to Participate in Two March Healthcare Conferences (GlobeNewswire)
Feb-27-25 08:20AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -7.14%
07:21AM	Aclaris: Q4 Earnings Snapshot (Associated Press Finance)
06:59AM	Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Feb-12-25 06:50AM	New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 (GlobeNewswire)
Jan-30-25 04:01PM	Aclaris Therapeutics Announces Formation of New Scientific Advisory Board (GlobeNewswire)
Jan-06-25 04:30PM	Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-24 04:30PM	Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-26-24 04:30PM	Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire) -9.02% +5.23%
Nov-20-24 05:11AM	Aclaris Therapeutics upgraded to Buy from Hold at Jefferies (TipRanks) -13.73%
Nov-19-24 09:30PM	Aclaris Therapeutics upgraded to Buy from Neutral at BTIG (TipRanks) +46.18%
03:27PM	Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments (Benzinga)
11:00AM	Aclaris Therapeutics secures global rights to Biosions antibodies (Pharmaceutical Technology)
Nov-18-24 08:50AM	Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets (PR Newswire) +53.17%
08:10AM	Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline (GlobeNewswire)
08:10AM	Aclaris Therapeutics Announces $80 Million Private Placement (GlobeNewswire)
Nov-06-24 08:05AM	Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:07AM	Aclaris: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Oct-09-24 07:02PM	Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc (GuruFocus.com)
Sep-18-24 06:52AM	Aclaris doses first subject in Phase IIa atopic dermatitis treatment trial (Clinical Trials Arena)
Sep-17-24 07:00AM	Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis (GlobeNewswire)
Sep-10-24 07:00AM	Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-07-24 08:15AM	Aclaris Therapeutics (ACRS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:20AM	Aclaris: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Jul-25-24 09:40AM	Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? (Zacks)
Jul-16-24 04:01PM	Aclaris Therapeutics Announces Sale of OLUMIANT Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million (GlobeNewswire)
Jul-02-24 01:27PM	Hedge Fund and Insider Trading News: Bill Ackman, David Einhorn, Saba Capital Management, Segantii Capital Management, Two Sigma Advisors, Falcon Investment Management, Aclaris Therapeutics Inc (ACRS), GigaCloud Technology Inc (GCT), and More (Insider Monkey)
Jun-06-24 07:00AM	Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-08-24 12:06PM	Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript (Insider Monkey) -8.96%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Leonard Braden Michael	10% Owner	Apr 23 '26	Sale	4.53	300,000	1,359,000	13,950,000	Apr 27 07:27 PM

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

M.D.Dr. Neal S. Walker D.O.

PresidentDr. Hugh M. Davis Ph.D.

Chief Financial OfficerMr. Kevin Balthaser

Chief Business OfficerMr. James Loerop

Chief Scientific OfficerDr. Roland Kolbeck Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Aclaris Therapeutics Inc

Upgrade your Finviz experience